Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-GLIO: Ipilimumab plus Temozolomide versus Temozolomide alone after chemoradiotherapy in newly diagnosed glioblastoma
2018-000095-15Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Ipilimumab + temozolomide with Temozolomide alone (2 arms). Primary endpoint: Overall survival. Status: unknown.
02
Drugs
ipilimumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2018-000095-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000095-15.